Rimonabant
Acomplia, Zimulti (rimonabant) is a small molecule pharmaceutical. Rimonabant was first approved as Acomplia on 2006-06-19. It has been approved in Europe to treat obesity. It is known to target G-protein coupled receptor 55 and cannabinoid receptor 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | 17 | 1 | — | 20 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | 1 | — | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 10 | — | 1 | 11 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 4 | — | — | 4 | |
| Dyslipidemias | D050171 | HP_0003119 | — | — | 4 | — | — | 4 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 2 | — | 1 | 3 |
| Weight loss | D015431 | HP_0001824 | — | — | 2 | — | — | 2 | |
| Fatty liver | D005234 | — | — | 2 | — | — | 2 | ||
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | 1 | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | 1 | — | — | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | 1 | — | — | 1 |
| Carotid stenosis | D016893 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | 1 | 2 | — | — | — | 2 | |
| Alcohol drinking | D000428 | EFO_0004329 | — | 1 | — | — | — | 1 | |
| Healthy volunteers/patients | — | — | 1 | — | — | — | 1 | ||
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Psychotic disorders | D011618 | F20.81 | — | 1 | — | — | — | 1 | |
| Smoking | D012907 | EFO_0003768 | F17 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Cannabis | D002188 | 1 | — | — | — | — | 1 | ||
| Psychological codependency | D017004 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RIMONABANT |
| INN | rimonabant |
| Description | Rimonabant is a carbohydrazide obtained by formal condensation of the carboxy group of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. It is a potent and selective cannabinoid receptor 1 (CB1R) antagonist. Besides its antagonistic properties, numerous studies have shown that, at micromolar concentrations rimonabant behaves as an inverse agonist at CB1 receptors. The drug was the first selective CB1 antagonist/inverse agonist introduced into clinical practice to treat obesity and metabolic-related disorders. It was later withdrawn from market due to CNS-related adverse effects including depression and suicidal ideation. It has a role as an anti-obesity agent, a CB1 receptor antagonist and an appetite depressant. It is a member of pyrazoles, a dichlorobenzene, a carbohydrazide, an amidopiperidine and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | cannabinol derivatives: CB (e.g., CB, CB2, etc.) cannabinoid receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,909 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
142 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more